NasdaqCM - Nasdaq Real Time Price • USD
Verastem, Inc. (VSTM)
As of 9:55 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 6 |
| Avg. Estimate | -1.03 | -0.96 | -3.76 | -2.7 |
| Low Estimate | -1.19 | -1.17 | -4.36 | -3.33 |
| High Estimate | -0.87 | -0.76 | -3.17 | -2.39 |
| Year Ago EPS | -0.96 | -1.37 | -3.96 | -3.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 7 | 7 |
| Avg. Estimate | -- | -- | -- | 29.97M |
| Low Estimate | -- | -- | -- | 7M |
| High Estimate | -- | -- | -- | 76.03M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.98 | -1.06 | -0.84 | -0.62 |
| EPS Actual | -0.96 | -1.37 | -0.75 | -1.02 |
| Difference | 0.02 | -0.31 | 0.09 | -0.4 |
| Surprise % | 2.00% | -29.20% | 10.70% | -64.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.03 | -0.96 | -3.76 | -2.7 |
| 7 Days Ago | -1.03 | -0.96 | -3.76 | -2.7 |
| 30 Days Ago | -0.94 | -0.97 | -3.51 | -2.54 |
| 60 Days Ago | -0.8 | -0.84 | -3.09 | -2.32 |
| 90 Days Ago | -0.86 | -0.88 | -3.09 | -2.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VSTM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -7.30% | -- | -- | 0.80% |
| Next Qtr. | 29.90% | -- | -- | 9.60% |
| Current Year | 5.10% | -- | -- | 4.50% |
| Next Year | 28.20% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 1.74% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/19/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 3/15/2024 |
| Maintains | Truist Securities: Buy to Buy | 11/15/2023 |
| Reiterates | B. Riley Securities: Buy to Buy | 9/29/2023 |
| Initiated | B. Riley Securities: Buy | 9/27/2023 |
| Reiterates | Mizuho: Buy to Buy | 8/29/2023 |
Related Tickers
KPTI Karyopharm Therapeutics Inc.
1.3000
+1.56%
CTMX CytomX Therapeutics, Inc.
1.7450
+0.87%
ABEO Abeona Therapeutics Inc.
7.55
+0.26%
RIGL Rigel Pharmaceuticals, Inc.
1.0600
+0.95%
ADAP Adaptimmune Therapeutics plc
1.0150
+12.98%
STRO Sutro Biopharma, Inc.
3.7500
-0.53%
IGMS IGM Biosciences, Inc.
7.27
-1.89%
CNTA Centessa Pharmaceuticals plc
10.50
-0.28%
MBIO Mustang Bio, Inc.
0.3762
+1.40%
ALXO ALX Oncology Holdings Inc.
16.05
+1.94%